These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21327725)

  • 21. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.
    Kei A; Liberopoulos EN; Mikhailidis DP; Elisaf M
    Int J Clin Pract; 2013 May; 67(5):412-9. PubMed ID: 23510018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM; Davidson MH; Setze CM; Kelly MT
    J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
    Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
    Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.
    Mindrescu C; Gupta RP; Hermance EV; DeVoe MC; Soma VR; Coppola JT; Staniloae CS
    Vasc Health Risk Manag; 2008; 4(6):1439-47. PubMed ID: 19337557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.
    Ferreira ES; Silva MA; Demonte A; Neves VA
    Lipids Health Dis; 2012 Jan; 11():11. PubMed ID: 22243700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.
    Agouridis AP; Filippatos TD; Kostapanos M; Kostara C; Tsimihodimos V
    Arch Med Sci Atheroscler Dis; 2024; 9():e26-e32. PubMed ID: 38434941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
    Domingos H; Cunha RV; Paniago AM; Souza AS; Rodrigues RL; Domingos JA
    Arq Bras Cardiol; 2012 Nov; 99(5):997-1007. PubMed ID: 23108642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Rizos CV; Liberopoulos EN; Tellis K; DiNicolantonio JJ; Tselepis AD; Elisaf MS
    Angiology; 2015 Jan; 66(1):36-42. PubMed ID: 24288364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
    Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
    Tuomilehto J
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S27-34. PubMed ID: 12880692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience].
    Bottaro EG; Caravello O; Scapellato PG; Stambulian M; Vidal GI; Loggia V; Scapellato JL; Thompson F; Cassetti I
    Enferm Infecc Microbiol Clin; 2008; 26(6):325-9. PubMed ID: 18588813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
    De Hert M; Kalnicka D; van Winkel R; Wampers M; Hanssens L; Van Eyck D; Scheen A; Peuskens J
    J Clin Psychiatry; 2006 Dec; 67(12):1889-96. PubMed ID: 17194266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.